David McAllister, DO
Interventional Cardiology · Des Moines, IANPI 1356323380
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (57.3%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Medtronic accounts for 81.2% of it on its own, with 23 other manufacturers making up the rest. Reporting peaked in 2021 at $25,760 and has fallen 89.4% since, to $2,738 in 2025. Among interventional cardiology clinicians in IA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 583 payments — averaging $94.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$44K
- Abbott$4K
- Edwards Lifesciences$2K
- Shockwave Medical, Inc$808
- Abiomed$702
- Teleflex LLC$361
- plus $2K from 18 others
Across 73 payments — averaging $1291.35 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Edwards Lifesciences$56K
- Medtronic$19K
- Heartflow, Inc.$14K
- Abbott$5K
- Abiomed$21
What the payments were for
- Speaking & faculty fees$31,42557%
- Travel & lodging$9,27517%
- Food & beverage$14,10726%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 301 | $44,480 |
| Abbott | 98 | $4,203 |
| Edwards Lifesciences | 73 | $2,146 |
| Shockwave Medical, Inc | 15 | $808 |
| Abiomed | 12 | $702 |
| Teleflex LLC | 8 | $361 |
| E.r. Squibb & Sons, L.L.C. | 14 | $356 |
| Novartis | 11 | $268 |
| Heartflow, Inc. | 8 | $264 |
| Cardiva Medical, Inc. | 6 | $263 |
| Philips North America LLC | 7 | $201 |
| Boston Scientific | 5 | $171 |
| Impulse Dynamics (USA) Inc. | 2 | $162 |
| Pfizer | 5 | $94 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 5 | $89 |
| Sanofi-aventis U.S. LLC | 2 | $55 |
| Acist Medical Systems, Inc. | 2 | $35 |
| AstraZeneca | 2 | $31 |
| Merck | 1 | $27 |
| Cardiovascular Systems Inc. | 2 | $24 |
| Penumbra, Inc. | 1 | $21 |
| Angiodynamics, Inc. | 1 | $18 |
| Boehringer Ingelheim | 1 | $17 |
| Chiesi USA, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CoreValve Evolut$31,279
- COREVALVE EVOLUT R$9,787
- Xience V coronary stent system$1,042
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$499
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$397
- Impella$396
- Mitra Clip system$310
- OPTIMIZER$292
- Vascular Lithotripsy$284
- Edwards SAPIEN 3 Transcatheter Heart Valve$252
- Ultreon$177
- CardioMEMS HF System$161
- SAPIEN 3 Ultra RESILIA$159
- Optis Coronary Imaging System$155
- PORTICO$153
- Tri-Ad$141
- NAVITOR$137
- Xience Sierra Coronary Stent System$126
- CAMZYOS$124
- LOTUS EDGE$115
How this compares
$54,806 in reported general payments places this provider in the 90th percentile of 64 interventional cardiology providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 74 | $52,479 |
| BrilintaTicagrelor | 70 | $29,400 |
| Repatha SureclickEvolocumab | 21 | $13,909 |
| Ranolazine ErRanolazine | 44 | $3,272 |
| Metoprolol Succinate | 201 | $1,829 |
| Enoxaparin Sodium | 12 | $1,204 |
| Ezetimibe | 32 | $918 |
| Atorvastatin Calcium | 153 | $908 |
| ClopidogrelClopidogrel Bisulfate | 162 | $731 |
| Rosuvastatin Calcium | 72 | $627 |
| Bisoprolol Fumarate | 33 | $562 |
| Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide | 49 | $436 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 42 | $431 |
| Lisinopril | 75 | $369 |
| Metoprolol Tartrate | 80 | $348 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $94 | $52,47974 claims |
| AstraZenecaBrilinta | $31 | $29,40070 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 64 interventional cardiology providers in Iowa.
Other interventional cardiology in Des Moines
- Atul ChawlaDes Moines$78K
- Daniel ShivapourDes Moines$54K
- Abdulrahman AbdulbakiDes Moines$43K
- Musab AlqasrawiDes Moines$6K
- Ravinder DerveshDes Moines$3K
- Hamza OglatDes Moines$924
- Aaron FromDes Moines$793
- Martin AronowDes Moines$232
- Nicolas ShammasDavenport$808K
- Eric DippelDavenport$100K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.